In this article, we will list the 5 Most Oversold Penny Stocks to Buy Right Now. Please visit 8 Most Oversold Penny Stocks to Buy Right Now if you would like to see the extended list and the methodology behind it.
5. Veritone, Inc. (NASDAQ:VERI)
On April 2, 2026, Veritone, Inc. (NASDAQ:VERI) announced the integration of Thorn Detect, a child sexual abuse material detection tool developed by Thorn, into its Intelligent Digital Evidence Management System suite. Jon Gacek said the partnership is a “critical step forward,” noting the integration is intended to help investigators identify evidence more quickly, shorten investigation cycles, and act on cases more efficiently.
On March 26, 2026, Veritone announced a multi-year agreement with Oracle to accelerate the deployment of enterprise AI and generative AI, establishing Oracle Cloud Infrastructure as a core platform for its next-generation solutions. The company said its Veritone Data Refinery platform has total new bookings and a near-term pipeline of over $50.0 million, up more than 25% from November 2025 estimates and 250% from Q4 2024.
Veritone expects Q1 revenue of $18.1M-$30.0M compared to the $34.3M consensus estimate. CEO Ryan Steelberg said the company is entering a “new phase” focused on execution, scale, and financial discipline, pointing to an improved balance sheet, an expanding VDR pipeline, and continued momentum in the public sector.
Veritone, Inc. (NASDAQ:VERI) provides artificial intelligence computing solutions and services across multiple international markets.
4. Plus Therapeutics, Inc. (NASDAQ:PSTV)
On March 31, 2026, D. Boral Capital downgraded Plus Therapeutics, Inc. (NASDAQ:PSTV) to Hold from Buy ahead of a 1-for-25 reverse stock split effective April 2. D. Boral Capital said the split does not change the company’s enterprise value but noted reverse splits in small-cap biotech “typically signal capital market strain,” can pressure liquidity, and may take time to rebuild the shareholder base.
On March 19, 2026, Plus Therapeutics announced new health economics data evaluating earlier detection and treatment of leptomeningeal metastases using its CNSide cerebrospinal fluid assay. The company said the analysis suggests earlier diagnosis and management may reduce overall healthcare costs by about 40%, driven by earlier intervention, improved treatment precision, and fewer hospitalizations, with results to be presented at the ISPOR 2026 Annual Meeting.
On March 12, 2026, Plus Therapeutics reported Q4 EPS of (29c), compared to the (4c) consensus estimate, with revenue of $5.21M versus $1.23M consensus. CEO Marc Hedrick said the company remains focused on its 2026 targets, highlighting CNSide commercial scale-up and REYOBIQ pivotal trial readiness as key priorities.
Plus Therapeutics, Inc. (NASDAQ:PSTV) develops and commercializes treatments for cancer, including radiotherapeutic candidates targeting central nervous system and other cancers.
3. Aether Holdings, Inc. (NASDAQ:ATHR)
On April 2, 2026, Litchfield Hills analyst Theodore O’Neill lowered the price target on Aether Holdings, Inc. (NASDAQ:ATHR) to $8 from $10 previously and still maintained a Buy rating on the shares.
The analyst said that the firm reduced its expectations for the pace of revenue growth following the first quarter earnings report of Aether Holdings, Inc. (NASDAQ:ATHR).
On March 31, 2026, Aether Holdings, Inc. (NASDAQ:ATHR) announced the formation of Aether DataHub, a joint venture with OORTech. Founder and Chief Executive Officer of OORTech, Chong Li, said that the partnership combines Aether Holdings, Inc. (NASDAQ:ATHR)’s financial media community with OORT’s AI data solutions to create a “living, evolving financial data layer” intended to support how financial intelligence is gathered and used.
Aether Holdings, Inc. (NASDAQ:ATHR) operates a financial technology platform, including SentimenTrader.com, which provides research analytics, data, and tools.
2. Jasper Therapeutics, Inc. (NASDAQ:JSPR)
On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the adjustment reflects updates across its small-to-mid cap biotechnology coverage as it reviewed Q2 catalysts, while noting stocks in the group are trading more on longer-horizon theses and broader FY26 catalysts.
On March 31, 2026, CEO Jeet Mahal said briquilimab has a “compelling and differentiated profile” in CSU and CIndU, with proof of concept in asthma, highlighting data from the BEACON study and open-label extension showing rapid and durable disease control. Jeet Mahal added that the company is finalizing dose selection for a Phase 2b/3 study in CSU and expects to begin patient enrollment in the second half of 2026, pending capital availability.
On March 23, 2026, UBS initiated coverage on Jasper Therapeutics with a Neutral rating and a $1.50 price target. UBS said the stock presents a balanced risk-reward over the next 12 months, citing competitive uncertainties while noting dose optimization data could provide upside.
Jasper Therapeutics, Inc. (NASDAQ:JSPR) develops therapeutics targeting mast and hematopoietic stem cell-driven diseases.
1. Vertical Aerospace Ltd. (NYSE:EVTL)
On March 30, 2026, Vertical Aerospace Ltd. (NYSE:EVTL) announced an agreement in principle for a financing package of up to $850M. The company said the package provides capital to support key milestones, including piloted transition flight, public flight demonstrations, development of its hybrid-electric demonstrator, expansion of the Vertical Energy Center, construction of its manufacturing facility, and production of its first full-scale certification aircraft. Vertical said it expects approximately $160M of near-term working capital, including $50M in equity raised and $30M available upon execution of facilities, along with existing cash and anticipated support from tax relief and grants.
The financing package includes four components: $50M in equity issuance, amendments to existing convertible secured notes with maturity extended to December 2030, and up to $50M in new notes, up to $250M in Series A convertible preferred equity from Yorkville, and an equity line of credit of up to $500M over 36 months. The company said the structure allows access to capital across multiple instruments and enables equity issuance over time, with definitive agreements expected by April 19, 2026.
On March 26, 2026, Canaccord lowered its price target on Vertical Aerospace to $9.50 from $11 and maintained a Buy rating after updating its model to reflect wider losses and higher cash burn. Canaccord said management attributed delays in completing a piloted full-transition flight in part to unusually heavy rainfall in Bristol.
Vertical Aerospace Ltd. (NYSE:EVTL) designs, manufactures, and sells electric vertical takeoff and landing aircraft for advanced air mobility markets.
While we acknowledge the potential of EVTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EVTL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 7 Heavily-Battered Consumer Stocks That Could Triple by 2027 and 10 Best 52-Week Low NYSE Stocks to Buy Now
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center